Cel The chronic inflammatory bowel disease (IBD), which encompasses Crohn's disease (CD) and ulcerative colitis is a common cause of gastrointestinal morbidity, with a combined prevalence of about 150-200 cases per 100,000 in Western Europe. The associated problems of chronic ill health, hospital admission, drug toxicity, and surgery present an important source of morbidity in the EU. Although the aetiology of these diseases is not currently clear, epidemiological and linkage data strongly suggest that a major contributing factor for IBD is genetic susceptibility. In fact, the first susceptibility gene for Crohn's disease (NOD2) was recently found. The current challenge is to translate the scientific progress of recent years into clinical benefit. Clinicians and patients are eagerly awaiting the development of novel, disease-specific therapies. To this end, we propose two major goals: (i) to evaluate the efficacy of GX305, a promising candidate drug for inflammatory diseases, as a treatment for CD. The aim of GX305 studies is to determine the potential of the drug as a CD treatment, and may therefore be of direct applicability for clinical practice. Our studies will determine the possible side effects and the effective dosage for treating patients. We also expect to describe the marker genotypes of both responders and non-responders to treatment; and (ii) to identify new targets for therapy tailored to individual patients. Very little is known about the molecular mechanisms of regulation and activation of NOD2 and its pathogenic variants, and there are no studies on the subcellular localisation of the protein under normal and pathological conditions, or in response to stimuli. We will address these basic mechanistic questions, with the long-term goal of providing new targets to reset the immunological balance in CD patients. In summary, we believe that success of this proposal will be of real significance in day-to-day life for both IBD patients and clinicians. Dziedzina nauki medical and health sciencesclinical medicinesurgerymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesmedical biotechnologygenetic engineeringnatural sciencesbiological sciencesbiochemistrybiomoleculesproteins Program(-y) FP6-MOBILITY - Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006 Temat(-y) MOBILITY-4.1 - Marie Curie European Reintegration Grants (ERG) Zaproszenie do składania wniosków FP6-2002-MOBILITY-11 Zobacz inne projekty w ramach tego zaproszenia System finansowania ERG - Marie Curie actions-European Re-integration Grants Koordynator FUNDACION INSTITUTO DE INVESTIGACION BIOMEDICA Y DESARROLLO TECNOLOGICO Wkład UE Brak danych Adres Paseo Mikeletegi, 61 bajo SAN SEBASTIAN Hiszpania Zobacz na mapie Koszt całkowity Brak danych
